Barely Significant
← all excerpts

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.

Nephrol Dial Transplant · 2017 · PMC5410979 · PMID 28186566

Europe PMCDOI
2
hedged sentences
0.1460
closest p · 2.9× alpha
0.1460
boldest claim

The sentences

showed a trendP = 0.146not close (p > 0.1)
The difference between the two groups showed a trend towards improvement (P = 0.146).

also in 53,322 other papers

a clear trendno p-value reported
When comparing the ITT and post hoc analysis data, it is obvious that (i) qualitatively, both sets show a virtually identical time course of ACR—the specific beneficial effect sets in 2 months after start of treatment, improves further until end of treatment and is maintained after cessation of dosing; (ii) quantitatively, the placebo-corrected effect of emapticap on ACR is most pronounced and statistically significant in the post hoc analysis, and maintained at least as a clear trend in the ITT population; and (iii) the improved separation in ACR between emapticap and placebo in the post hoc analysis is mainly due to reduced background noise in the placebo group.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.